The treat-to-target (T2T) strategy improved long-term survival of patients with pulmonary arterial hypertension (PAH). Little was known about applying the T2T strategy in primary Sjogren's syndrome-associated PAH (pSS-PAH). We investigated how to identify patients who are more likely to reach the treatment goals in a cohort of pSS-PAH. In this way, we explored the possibility of implementing T2T in pSS-PAH. Data were retrospectively collected from patients visiting our center between 2007 and 2017. PAH was confirmed by right heart catheterization (RHC). Patients were treated following the T2T strategy. PAH treatment goals were defined by the 5th World Symposium on Pulmonary Hypertension. The primary end point was reaching the PAH treatment goals. Of the 62 patients enrolled, 98.4% were female, with a mean age of 38.9 ± 9.1 years at the diagnostic RHC. The median disease duration of pSS was 46 months (0-365), while the median disease duration of PAH was 12 months (0-149). Following the T2T strategy, 32 (50%) patients achieved the treatment goals. The 1-, 3-, and 5-year cumulative rates of reaching the goals were 40.6, 67.4, and 73.9%, respectively. Predictive factors included using immunosuppressants (HR 4.715,, p = 0.037) and right ventricular anterior-posterior diameter (RV-APD) > 30 mm at baseline (HR 0.426, 95% CI 0.188-0.968, p = 0.042). The results provide strong evidence that patients who received immunosuppressants are more likely to reach the treatment goals. In contrast, impaired RV structure correlates to worse treatment response. The T2T strategy is effective in pSS-PAH.
Introduction
Pulmonary arterial hypertension (PAH) is a rare and severe complication of connective tissue disease (CTD). Compared with idiopathic PAH (IPAH), CTD-PAH has worse response to the PAH therapies and poorer prognosis [1, 2] . In Western populations, the prevalence of systemic sclerosis-associated PAH (SSc-PAH) was higher than other types of CTD-PAH [2] [3] [4] . In Asian populations, however, a different distribution of underlying CTDs was reported. Data from Korea and Japan identified systemic lupus erythematosus (SLE) as the most common underlying disease [5, 6] and primary Sjögren's syndrome (pSS) as one major associated CTD [6] . Peking Union Medical College Hospital (PUMCH) established the cohort of CTD-PAH in 2006 [7] . In our published cohort, the most common underlying CTD was SLE (58.4%), followed by SSc (26.3%) and pSS (15.3%) [7] . This trend remained consistent in two other Chinese cohorts [8, 9] . Preliminary survival analysis revealed that pSS-PAH had better prognosis than SSc-PAH, whereas worse than SLE-PAH [7] . However, little was known about pSS-PAH due to the limited data.
The treat-to-target (T2T) strategy of PAH was originally promoted by Hoeper et al. in 2005 [10] . The essential idea of T2T is that PAH requires regular monitoring and treatment escalation if the treatment goals are not met. Since then, researches have focused on optimizing the treatment approaches for PAH, and the long-term survival of PAH was improved under this strategy [11, 12] . However, challenges are met in the subgroup of pSS-PAH. Cohorts of pSS-PAH are rare. Few case series reported the clinical manifestations and outcomes of pSS-PAH [13] [14] [15] ; however, most were limited by lacking the diagnostic right heart catheterization (RHC). The physiopathology and clinical features of PAH in pSS still await much investigation. In addition, there is no specific guideline for the treatment in pSS-PAH. No previous study, to our knowledge, has reported the therapeutic response or pertinent clinical markers in patients with pSS-PAH. We aimed to investigate how to identify the patients who are more likely to reach the treatment goals following the T2T strategy. In this way, we explored the possibility of applying the T2T strategy in pSS-PAH.
Methods

Study population
Patients with pSS-PAH visiting the Department of Rheumatology, PUMCH, during August 2007 and May 2017 were enrolled in this study. The baseline was defined as the date of the diagnostic RHC. Patients were followed up every 3 to 6 months at the Rheumatology clinic of PUMCH. This study was approved by the Medical Ethics Committee of PUMCH. All patients entering the cohort signed the written informed consent.
The diagnosis of pSS was confirmed with the revised classification criteria proposed by the American-European Consensus Group in 2002 [16] . The evaluation of pSS was achieved through SS patient activity index (ESSDAI) and SS disease damage index (SSDDI). ESSDAI evaluates the number, importance, and severity of the involved organs [17, 18] . SSDDI evaluates the irreversible damage of the disease [19] . According to the guidelines of 2015 European Society of Cardiology/European Respiratory Society, PAH was defined as mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at rest, pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 3 Wood units, as evaluated by RHC. Exclusion criteria included (1) fulfilling the classification criteria of other CTDs such as SLE, SSc, and mixed connective tissue disease (MCTD); (2) evidence of cardiac structural abnormality that can cause PAH; (3) chronic thromboembolic disease confirmed by ventilation and perfusion scanning and/or computed tomographic pulmonary angiography; (4) severe interstitial lung disease (ILD) revealed by chest high-resolution computed tomography (HRCT) and pulmonary function test (PFT). Patients were excluded if the total lung capacity (TLC) was < 60% of predicted and were included if the TLC was > 70% of predicted. Patients with TLC between 60 and 70% of predicted were included if the HRCT reveled only minimal interstitial fibrosis.
Data collection
All data were collected in a protocol-directed method by welltrained rheumatologists. A uniform evaluation chart was designed to collect patients' baseline demographics, clinical manifestations, major comorbid conditions, laboratory tests, autoantibody results, hemodynamics data, and treatment regimens. Extra-glandular, extra-thoracic manifestations included (1) non-erosive arthritis; (2) purpura; (3) peripheral neuropathy; (4) hepatic involvement; (5) renal involvement; (6) hematological involvement: hemocytopenia, hyperglobulinemia, hypocomplementemia, and lymphoma. Laboratory tests included complete blood count, liver function test, renal function panel, urine analysis, erythrocyte sedimentation rate (ESR), hypersensitive C-reactive protein (hsCRP), immunoglobulin, and complement. All tests were conducted by the Laboratory Department of PUMCH. The evaluation of PAH included transthoracic echocardiography (TTE), modified New York Heart Association functional classification (NYHA FC), PFT, 6-min walking distance (6MWD) [20] , serum brain natriuretic peptide (BNP), and N terminal-pro BNP (NT-proBNP). All patients conducted RHC; pertinent parameters included right atrial pressure (RAP), mPAP, PAWP, PVR, cardiac output (CO), and cardiac index (defined as CO divided by body surface area). To evaluate ILD, all patients performed HRCT and PFT. PFT examined forced vital capacity (FVC), TLC, and diffusing capacity for carbon monoxide (DLCO). For the treatment regimens, glucocorticoids and immunosuppressants were documented for the dosage and administration route. Immunosuppressants included cyclophosphamide, mycophenolate mofeil, methotrexate, leflunomide, and tacrolimus. Basic treatment for PAH was given as needed, such as diuretics, digoxin, anticoagulant therapy, and oxygen. PAH-targeted therapies were recorded and analyzed, including endothelial receptor antagonists (ERAs), phosphodiesterase type5 (PED5) inhibitors, and prostacyclin derivatives. Combination therapy was defined as immunosuppressive treatment combining with PAH-specific therapies.
Follow-up and outcome
All patients were followed up every 3 to 6 months at the Department of Rheumatology, PUMCH. The primary endpoint was reaching the treatment goals of PAH. The composite treatment goals were defined according to the 5th World Symposium on Pulmonary Hypertension [21] as follows: (1) modified NYHA FC I or II; (2) normal or near-normalized structure and function of right ventricle (RV) demonstrated by TTE or cardiac MR: RV anterior-posterior diameter (RV-APD) < 30 mm, or RV transverse diameter (RV-TD) < 40 mm; (3) 6MWD of > 380 to 440 m; (5) normal BNP levels: BNP < 50 pg/ml, or NT-proBNP < 300 pg/ml; (4) the repeated RHC was not mandatory. If applying, normal RV function showed by hemodynamic parameters: RAP < 8 mmHg and cardiac index > 2.5 L/min/m 2 . Cardiopulmonary exercise testing was not involved in the treatment goals because it is not routinely performed in our center.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) version 24.0 (Chicago, IL, USA) was used for data processing and analysis. Continuous variables were presented as mean and standard deviations (SD) or medium (range) and were compared by independent sample t test or Mann-Whitney U test. Category variables were presented as frequencies and were compared by Pearson chi-squared test. One-, 3-, 5-year cumulative rates of goal reaching were calculated. Univariate and multivariate Cox proportional regression analysis was used to identify predictive factors among age, disease duration, clinical manifestations, lab tests, TTE, PFT, 6MWD, modified NYHA FC, RHC data, and the treatment regimens (glucocorticoids, immunosuppressants, and PAH-targeted therapies). Results were presented as odds ratios and 95% confidence intervals (CIs). A two-tailed p value of less than 0.05 was considered statistically significant.
Results
Study population
Overall, 64 patients with pSS-PAH fulfilled the criteria. Two patients failed to continue follow-up and were removed from the cohort. Of the 62 patients enrolled, 61 (98.4%) were female. The mean age at the diagnostic RHC was 38.9 ± 9.1 years with the range of (26-62). The median disease duration of pSS was 46 months (0-365). In 51.6% of the patients, PAH was the initial manifestation. PAH was confirmed 12 months (0-149) later than its onset (Table 1) .
Information pertinent to the diagnosis of pSS is also shown in Table 1 . Overall, 43 patients had positive Schirmer test among 58 patients who completed the test (74.1%). All of the 17 patients who performed labial salivary biopsy reported positive results (100%). Anti-SSA/SSB antibodies were detected in 55 out of 61 patients (90.2%). Raynaud phenomenon was found in 20 (32.3%) patients. Among 61 patients who were detected for anti-U1RNP antibodies, 12 (19.7%) were positive. However, no patient in this cohort had Bpuffy finger,^arthritis, myositis, or esophageal disease supporting the diagnosis of MCTD. Anti-centromere antibody, antiScl70 antibody, and anti-phospholipid antibodies were negative in all patients. The extra-glandular, extra-thoracic manifestations were analyzed: non-erosive arthritis (1.6%), purpura (6.5%), hepatic involvement (8.1%), renal involvement (6.5%), peripheral neurology (1.6%), hemocytopenia (51.6%), hypocomplementemia (19.6%), and hyperglobulinemia (60.3%). Major comorbid conditions included arterial hypertension (6.5%), diabetes mellitus (1.6%), and chronic kidney disease (3.2%). No arterial vascular events or malignancy was found in this cohort (Table 1) .
PAH evaluation and treatment regimens of pSS-PAH
Nearly half of the patients (45.2%) were assessed as NYHA FC III to IV at baseline ( Table 2 ). The mean 6MWD was 418 ± 106 m. According to HRCT, 5 (8.1%) patients presented with the evidence of ILD. However, the extent of disease on the image was minimal and was without clinical significance. The pulmonary function was normal or only slightly impaired: mean FVC was 85.9 ± 9.6% of predicted, and mean DLCO was 59.8 ± 11.9% of predicted. In hemodynamic profile, mPAP was 49.5 ± 9.4 mmHg, PVR was 11.6 ± 5.1 WU, and cardiac index was 2.5 ± 0.7 L/min/m 2 . The treatment regimens involved the treatment for both pSS and PAH. Almost all patients (56, 90.3%) received glucocorticoids, and 44 (71.0%) patients had mid-dose glucocorticoids or higher (prednisone ≥ 0.5 mg/kg/day). Among the 49 patients who received immunosuppressants, 45 (72.6%) received cyclophosphamide, 1 (1.6%) received methotrexate, 1 (1.6%) received leflunomide, 1 (1.6%) used Tacrolimus, and 1 (1.6%) used mycophenolate mofeil. On diagnosis of PAH, 93.5% patients were administrated with at least one PAH-targeted therapies, including sildenafil (30.6%), tadalafil (33.9%), bosentan (24.2%), ambrisentan (6.5%), or other medications (8.1%). Forty-two (74.2%) patients received combination therapy, which was defined as immunosuppressive treatment combining with PAH-specific therapies.
For patients who received immunosuppressants, the level of IgG was significantly lower 3 months after treatment than at baseline (12.1 ± 3.9 vs. 20.2 ± 8.4 g/L, p < 0.001), while the level of C3 was comparable before and after treatment (1.02 ± 0.22 vs. 1.00 ± 0.27 g/L, p = 0.326). Comparing the patients who received immunosuppressants with those who did not use immunosuppressant, the level of IgG after treatment also differed significantly (12.1 ± 3.9 vs. 16.6 ± 3.0 g/L, p = 0.007).
Predictive factors of achieving the PAH treatment goals
Thirty-one patients (50%) in this cohort achieved the composite PAH treatment goals. The 1-, 3-, and 5-year cumulative rates of reaching the goals were 40.6, 67.3, and 73.9%, respectively. The median time to reaching the goals was 15.2 months (1-57.1). Table 3 shows the comparison of baseline demographics, clinical characteristics, and treatment regimens between two groups of patients: patients who reached the treatment goals were classified into group 1, and patients who failed to meet the goals into group 2. The time between onset of pSS and the diagnostic RHC was shorter in group 1 than that in group 2 (47.7 ± 49.9 vs 87.9 ± 89.6 months, p = 0.034). Patients in group 1 seemed to have a better hemodynamic profile with a lower RAP (5.2 ± 3.6 vs 8.4 ± 5.8 mmHg, p = 0.023). Consistently, mPAP was also lower in group 1, though not significantly. Markedly (Table 4) . Multivariate Cox regression analysis confirmed that the independent predictive factors of reaching the goals were using immunosuppressants (HR 4.715, 95% CI 1.101-20.192, p = 0.037) and baseline RV-APD > 30 mm (HR 0.426, 95% CI 0.188-0.968, p = 0.042) ( Table 5) .
To confirm the impact of immunosuppressants and baseline RV-APD, we evaluated the cumulative rates of achieving the treatment goals. The 1-, 3-, and 5-year rates of reaching the goals were 48.8, 78.4, and 83.8%, respectively, for patients who received immunosuppressant; 10.0, 21.2, and 21.2% respectively for patients who did not (Fig. 1a) . The 1-, 3-, and 5-year rates of reaching the goals were 63.3, 75.5, and 75.5% respectively for patients who had baseline RV-APD ≤ 30 mm; 30.5, 54.4, and 63.5% respectively for patients who had RV-APD > 30 mm at baseline (Fig. 1b) .
Discussion
This study focused on applying the treat-to-target (T2T) strategy in patients with pSS-PAH. We presented the largest cohort of pSS-PAH confirmed by RHC. Our results showed that patients who received immunosuppressants were more likely to reach the PAH treatment goals, subsequently to obtain a better prognosis. In contrast, patients with RV-APD larger than 30 mm at baseline tended to have worse response to treatment. Our study is the first to report the predictive factors of achieving the treatment goals in patients with pSS-PAH. We also confirm that T2T strategy is effective in pSS-PAH.
The last decade was marked by therapeutic advances in PAH with the T2T strategy. Historically, escalating treatment for PAH was mainly based on clinical deterioration. Promoted by Hoeper et al. in 2005 [10] , the T2T strategy uses known prognostic indicators of PAH as the goals of treatment. Guided by T2T, patients with PAH have achieved better survival. However, PAH encompasses heterogenetic subgroups. In CTD-PAH, the most investigated underlying disease is SSc. Cohort studies and meta-analyses reported that the parameters classically associated with the severity of IPAH, including 6MWD, mPAP, cardiac index, and RAP, were also prognostic factors in SSc-PAH [22] [23] [24] [25] . For pSS-PAH, however, it is still difficult to identify the patients who may benefit from the treatment more than others due to a paucity of data. The 1-, 3-, and 5-year cumulative rates of achieving the PAH treatment goals in our cohort of pSS-PAH were 40.6, 67.3, and 73.9%, respectively. These rates indicate that most patients reached the goals within 1 year after the treatment started. Previous studies on PAH have confirmed that achieving the treatment goals is associated with better clinical outcomes [26, 27] . Consistently, two sets of recently published guidelines also provided evidence-based recommendations for comprehensive prognostic evaluation and achieving PAH treatment goals [28, 29] . The data from our study reinforced the importance of early, active intervention following the T2T strategy in patients with pSS-PAH in order to achieve better prognosis.
We found that using immunosuppressants is independently predictive to reaching the treatment goals. Similarly, a Japanese cohort indicated that intensive immunosuppressive therapy could improve the hemodynamic profiles in patients with CTD-PAH. Thirteen patients were recruited, among which 4 had pSS. Six patients achieved nearly normal mPAP that maintained for at least 12 months after treatment [30] . In our cohort, since 45 out of 49 patients received cyclophosphamide, we also involved cyclophosphamide in multivariate analysis, but the result was not significant (HR 1.841, 95% CI 0.528-6.419, p = 0.338). Limited by the size of the cohort, it was difficult to inspect which specific immunosuppressive agent would have an impact on achieving the treatment goals. Currently, there is no specific guideline for the management of patients with pSS-PAH. We propose that immunosuppressants should be introduced as a part of standardized treatment approach for pSS-PAH. Moreover, our finding also gives clue to the pathogenesis. pSS is characteristic of lymphocytic infiltration of the salivary glands. Abnormally activated B cells promote plasma cell secretion of immunoglobulins and various autoantibodies [31, 32] . The role of T-cells was with divergent conclusions, especially about the regulatory T-cells and T-helper 17 cells [33] . However, the T cell activation was confirmed. On the other hand, the mechanisms of PAH in pSS have not been well elucidated. PAH in CTD is not homogenous but intertwines the dysregulation in autoimmune and the remodeling of pulmonary vasculature. Histopathology study showed that SSc/MCTD-PAH was generally accompanied with fibrosis, whereas fibrosis in SLE-PAH was rare and mild [34] . Hypotheses on mechanism included endothelial dysfunction, immune complex accumulation, necrotizing vasculitis, and imbalances of endothelial vasoactive molecules [35] [36] [37] . In pSS-PAH, little was known due to the lack of data. The results of our study highlighted the essential role of autoimmune process in the pathogenesis of pSS-PAH, providing evidence for future studies.
We also identified that patients with RV-APD larger than 30 mm at baseline are less likely to achieve the PAH treatment goals. Similarly, Ghio et al. found that an increased RV diameter is prognostic to poor survival in patients with IPAH [38] . It is well established that an elevated RVSP or PASP by echocardiography is neither sensitive nor specific to diagnose PAH [39] . However, the structure of RV is reliable to evaluate the severity of PAH. Noninvasive echocardiography is widely available to provide information about RV function and can estimate RV pressures [40] . Noticeably, RV failure is the main cause of mortality in PAH. Decreased RV ejection has been proved to strongly associate with poor survival in IPAH [41] . Although cardiac magnetic resonance remains the gold standard for evaluating RV volumes, it is expensive and less accessible. Therefore, echocardiography remains an important tool for screening to detect PAH and for assessment during follow-up [28, 42] . Given the relatively higher prevalence and greater mortality of SSc-PAH, SSc is now the only CTD with recommended screening guidelines [28] . The present study shows that echocardiography provides additional information other than detecting PAH in pSS. An impaired RV morphology at baseline helps identify patients with pSS-PAH who may not respond well to the initial treatment and may need particular attention. This is the practical implication that can help physicians to manage the patients with pSS-PAH more efficiently.
There are several limitations of this study. First, PUMCH is a tertiary center, and there is a possibility of referral bias. Some patients enrolled in this study were referred from local hospitals or cardiologists and have never undergone screening for PAH. Therefore, patients in this study appeared to have severe PAH, based on the RHC performance. An approach of early detection is required to recognize the patients in the early stage of PAH. Second, this study is single centered and was limited by size. Future multicenter cohorts are in need to explore independent prognostic factors of pSS-PAH and to further validate the T2T strategy.
In conclusion, we characterize the largest cohort of pSS-PAH confirmed by RHC. This is the first study to describe predictive factors of achieving the PAH treatment goals in pSS-PAH following the T2T strategy. We provide strong evidence that patients who received immunosuppressants are more likely to reach the treatment goals. In contrast, an impaired RV structure correlates to worse treatment response. We also confirm that the T2T strategy is effective in pSS-PAH. Future studies are required to optimize the therapeutic strategies for pSS-PAH in order to further shift the survival curve to the right.
